Global Pharmacogenetic Testing Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 11,442.40 |
 CAGR |
% |
| Principais participantes do mercado |
>Global Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 and VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX and MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services) - Industry Trends and Forecast to 2030.
Pharmacogenetic Testing Market Analysis and Size
The global pharmacogenetic testing market is expected to gain market growth in the forecast period of 2023 to 2030. The market is fueled by the increasing adoption of personalized medicine which is a market that needed the pharmacogenetic testing market.
Integrating Electronic Health Records (EHRs) is a significant driver for the market growth. An increase in chronic and complex diseases is expected to create opportunities for market growth Data Bridge Market Research analyses that the market is growing with a CAGR of 8.7% in the forecast period of 2023 to 2030 and is expected to reach USD 11,442.40 million by 2030. Advancements in genomic technologies are expected to drive the market's expansion.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable 2015-2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 and VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX and MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services) |
|
Countries Covered |
EUA, Canadá, México, França, Alemanha, Espanha, Itália, Reino Unido, Espanha, Holanda, Rússia, Turquia, Suíça, Resto da Europa, China, Japão, Tailândia, Índia, Coreia do Sul, Austrália, Singapura, Indonésia, Filipinas , Malásia , Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, Emirados Árabes Unidos, Arábia Saudita, África do Sul, Israel, Egito e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
PerkinElmer Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Dynamic DNA Laboratories, Sonic Healthcare, QIAGEN, Eurofins Scientific, 23andMe, Inc, OneOme, BGI, PacBio, MD Labs, GENEWIZ, PGXT, Luminex Corporation e Myriad Genetics, Inc., entre outros |
Definição de mercado de testes farmacogenéticos
Os testes farmacogenéticos incluem serviços que examinam o perfil genético de uma pessoa para verificar como os genes de uma pessoa afetam a reação da mesma a determinados medicamentos. Este teste genético especializado identifica variações genéticas específicas que podem afetar o metabolismo, a eficácia e os possíveis efeitos secundários de diferentes medicamentos. Os profissionais de saúde podem personalizar as seleções e dosagens dos medicamentos para um doente, de forma a melhorar os resultados do tratamento, reduzir os efeitos secundários e aumentar a eficácia global dos medicamentos. Isto é feito estando ciente das predisposições genéticas do paciente. A qualidade dos cuidados de saúde e os resultados dos doentes podem melhorar devido a esta seleção personalizada de medicamentos e abordagem de dosagem.
Dinâmica do mercado de testes farmacogenéticos
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Aumento da adoção da medicina personalizada
Os testes farmacogenéticos desempenham um papel crucial na medicina personalizada, adaptando os tratamentos medicamentosos à composição genética de um indivíduo. Esta abordagem inovadora envolve a análise das variações genéticas de um indivíduo, que podem ter impacto na forma como metaboliza e responde a medicamentos específicos. Estas diferenças genéticas podem influenciar a eficácia dos medicamentos e os potenciais efeitos secundários, tornando os testes farmacogenéticos uma ferramenta valiosa para planos de tratamento personalizados.
Os prestadores de cuidados de saúde podem identificar marcadores genéticos que determinam a forma como o seu corpo processa e utiliza os medicamentos, examinando o perfil genético único de uma pessoa. Esta informação permite a personalização da seleção e dosagens dos medicamentos para otimizar os resultados do tratamento. Por exemplo, alguns indivíduos podem ter variantes genéticas que os tornam mais sensíveis a determinados medicamentos, necessitando de doses mais baixas para atingir o efeito terapêutico desejado sem reações adversas. Por outro lado, algumas variações genéticas podem exigir doses mais elevadas para o mesmo efeito. Esta abordagem personalizada minimiza a “tentativa e erro” frequentemente associada à seleção de medicamentos, reduzindo o risco de reações adversas e melhorando a eficácia do tratamento. Capacita os profissionais de saúde para tomarem decisões informadas e prescreverem medicamentos com maior probabilidade de funcionarem bem para os doentes com base nas suas predisposições genéticas. Em última análise, os testes farmacogenéticos contribuem significativamente para o paradigma da medicina personalizada, revolucionando os cuidados de saúde ao promover estratégias de tratamento mais precisas e individualizadas para melhores resultados para os doentes.
Assim, o mercado está a beneficiar deste aumento da procura, assistindo a um aumento consistente das atividades de I&D para criar soluções de testes mais abrangentes e precisas. Os avanços tecnológicos, como o Sequenciamento de Próxima Geração (NGS) e outras técnicas de diagnóstico molecular, aumentam ainda mais a precisão e a acessibilidade destes testes. O resultado é uma relação de reforço mútuo entre a ascensão da medicina personalizada e o mercado florescente, com ambos a impactarem significativamente o panorama da saúde, prometendo um futuro onde os tratamentos são personalizados, eficazes e centrados no paciente, o que deverá impulsionar o crescimento do mercado.
- Avanços nas tecnologias genómicas
O aumento contínuo da inovação genómica melhorou significativamente a precisão, a velocidade e a relação custo-eficácia dos testes genéticos. O Sequenciamento de Próxima Geração (NGS) e outras técnicas de diagnóstico molecular de ponta surgiram como ferramentas essenciais, revolucionando a forma como a informação genética é analisada e interpretada. A integração destas tecnologias genómicas avançadas reforçou a precisão e o alcance dos testes farmacogenéticos, permitindo uma avaliação abrangente do perfil genético de um indivíduo. Isto, por sua vez, capacita os profissionais de saúde para tomarem decisões informadas sobre a seleção de medicamentos, dosagem e estratégias de tratamento adaptadas à composição genética única de um paciente.
Além disso, a tecnologia de edição genética CRISPR-Cas9 mostrou-se promissora no estudo do impacto funcional de variantes genéticas específicas. Esta tecnologia permite aos investigadores modificar os genes com precisão, imitando certas variações genéticas e elucidando os seus efeitos no metabolismo e na resposta aos medicamentos. Estes avanços contribuem colectivamente para o refinamento e expansão do mercado, aproximando-se de um futuro onde os medicamentos serão adaptados a cada indivíduo com base no seu modelo genético único, o que deverá impulsionar o crescimento do mercado.
Oportunidade
- Integração com Registos de Saúde Eletrónicos (EHRs)
A integração perfeita permite o armazenamento eficiente e centralizado de dados genéticos, juntamente com registos de saúde abrangentes dos pacientes. Esta fusão aumenta a acessibilidade e a usabilidade da informação farmacogenética para os profissionais de saúde, permitindo-lhes tomar decisões baseadas em dados em tempo real. Os médicos podem aceder prontamente a informações genéticas durante o planeamento do tratamento, garantindo a prescrição de medicamentos que se alinhem com a composição genética única do paciente. Os ganhos de eficiência alcançados através desta integração aceleram a adoção de testes farmacogenéticos, contribuindo para melhorar os cuidados prestados aos doentes, simplificar os fluxos de trabalho e, em última análise, promover o crescimento do mercado.
Além disso, a integração com EHR facilita a investigação e a análise de dados numa escala mais ampla. Os dados genéticos agregados e desidentificados nos RSE podem ser aproveitados para investigação e estudos clínicos, impulsionando os avanços na farmacogenómica. As empresas farmacêuticas, as instituições de investigação e os prestadores de cuidados de saúde podem utilizar estes dados para melhorar o desenvolvimento de medicamentos, validar as associações genéticas e otimizar as estratégias de tratamento. Esta colaboração entre o mercado e os EHR alimenta a inovação. Promove um ecossistema sinérgico que beneficia o sector da saúde e impulsiona o mercado através de investigação melhorada, desenvolvimento de produtos e tomada de decisões baseada em dados, o que deverá criar oportunidades para o crescimento do mercado.
Restrição/Desafio
- Dependência do Especialista Médico e Genómico para Interpretação de Resultados
The market faces a notable constraint in the form of heavy reliance on medical and genomic experts for result interpretation. The intricate nature of genetic data necessitates specialized knowledge and expertise for accurate and meaningful understanding. The correct interpretation of pharmacogenetic test results heavily depends on highly skilled professionals, including geneticists, pharmacologists, and genomics experts. This dependency poses a challenge in terms of scalability and widespread adoption of pharmacogenetic testing. The limited pool of qualified experts and the time and effort required for precise interpretation often delay providing actionable insights to healthcare practitioners and patients. Furthermore, this reliance on experts can lead to increased costs and resource utilization, hindering the seamless integration of pharmacogenetic testing into routine clinical practice. Overcoming this restraint calls for advancements in automated data analysis tools, user-friendly interfaces, and comprehensive educational programs to empower a broader spectrum of healthcare professionals in accurately interpreting and utilizing pharmacogenetic test results.Thus, the market holds immense promise in tailoring drug therapies for individuals based on their genetic makeup. A critical challenge lies in the dependency on medical and genomic experts for interpreting test results. The complexity of genetic data requires specific expertise, making it challenging to interpret results and make clinical decisions, which is expected to restrain market growth.
Recent Development
- In May 2023, PerkinElmer Inc. announced the launch of Revvity, Inc. as a provider of science-based solutions that uses advancements in the diagnostics and life sciences to enhance people's lives worldwide. Previously, the business was connected to PerkinElmer, Inc. Customers of Revvity come from various industries, including pharma and biotech, diagnostic labs, academia, and governmental organizations. Revvity offers reagents, consumables, assays, instruments, and software
- In October 2022, PacBio and Twist Bioscience Corporation announced the availability of an initial portfolio of off-the-shelf long-read gene panels. These fixed Twist Alliance panels are made to efficiently and cost-effectively capture target areas. In addition, customers will be able to create a panel of their design that is fully adaptable and scalable for sequencing using PacBio HiFi reads
Global Pharmacogenetic Testing Market Scope
The global pharmacogenetic testing market is segmented into eight notable segments based on type, gene type, drug type, sample, therapeutic area, application, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications
Type
- Whole Genome Sequencing
- Whole Exome Sequencing
- Array-Based Tests
- Single Gene Tests
On the basis of type, the market is segmented into whole genome sequencing, whole exome sequencing, array-based tests, and single gene tests.
Gene Type
- CYP2C19
- CYP2D6
- CYP2C9 and VKORC1
- CYP1A2
- HLA-B*1502
- HLA-B*5701
- CYP2D
- OPRM1
- ONCOTYPE DX® and MAMMAPRINT®
- DRD3
- D4D4
- SLC6A4
- HTR2A/C
- TMPT
- Others
On the basis of gene type, the market is segmented into CYP2C19, CYP2D6, CYP2C9 and VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX and MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and others.
Drug Type
- Prescription Drugs
- Nutraceuticals
- Recreational Drugs
- Herbal Supplements
- Vitamins
- Over-the-Counter Medications
On the basis of drug type, the market is segmented into prescription drugs, nutraceuticals, recreational drugs, herbal supplements, vitamins, and over-the-counter medications.
Sample
- Blood
- Saliva
On the basis of sample, the market is segmented into blood and saliva.
Therapeutic Area
- Cardiology
- Gastroenterology
- Anesthesiology
- Genomics
- Endocrinology
- Immunology & Hypersensitivity
- Dermatology
- Gynecology
- Oncology
- Neurology
- Others
On the basis of therapeutic area, the market is segmented into cardiology, gastroenterology, anesthesiology, genomics, endocrinology, immunology & hypersensitivity, dermatology, gynecology, oncology, neurology, and others.
Application
- Clinical Practice
- Drug Development
- Drug Regulation
On the basis of application, the market is segmented into clinical practice, drug development, and drug regulation.
End User
- Healthcare Providers
- Pharmaceutical & Biotechnology Companies
- Centres and Academic Institutes
- Others
On the basis of end user, the market is segmented into healthcare providers, pharmaceutical & biotechnology companies, research centers and academic institutes, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacies
- Mail-Order Pharmacies
- Direct-to-Customer Services
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacies, mail-order pharmacies, and direct-to-customer services.
Regional Analysis/Insights: Pharmacogenetic Testing Market
The global pharmacogenetic testing market is analyzed, and market size insights and trends are provided on the basis of type, gene type, drug type, sample, therapeutic area, application, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, France, Germany, Spain, Italy, U.K., Spain, Netherlands, Russia, Turkey, Switzerland, Rest of Europe, China, Japan, Thailand, India, South Korea, Australia, Singapore, Indonesia, Philippines, Malaysia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, U.A.E., Saudi Arabia, South Africa, Israel, Egypt, and Rest of Middle East and Africa.
Prevê-se que os EUA dominem a região da América do Norte devido à sua infra-estrutura avançada e à extensa rede de centros de infra-estruturas de saúde de alta qualidade. Prevê-se que a Alemanha domine a região da Europa devido à sua crescente I&D associada à biotecnologia e à saúde. Espera-se que o Japão domine a região Ásia-Pacífico devido à sua crescente procura e à crescente consciencialização em relação ao mercado de testes farmacogenéticos.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas regionais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo do mercado de testes farmacogenéticos e análise de ações
O panorama competitivo do mercado global de testes farmacogenéticos fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença regional, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas no mercado.
Alguns dos principais players que operam no mercado global de testes farmacogenéticos são a PerkinElmer Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Dynamic DNA Laboratories, Sonic Healthcare, QIAGEN, Eurofins Scientific, 23andMe, Inc, OneOme, BGI, PacBio, MD Labs, GENEWIZ, PGXT, Luminex Corporation e Myriad Genetics, Inc., entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’SFIVE FORCES
4.3 INDUSTRY INSIGHTS AND STRATEGIC ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING ADOPTION OF PERSONALIZED MEDICINE
5.1.2 ADVANCEMENTS IN GENOMIC TECHNOLOGIES
5.1.3 INCREASING CHRONIC AND COMPLEX DISEASES
5.1.4 ROLE OF PHARMACOGENETIC TESTING IN DRUG DISCOVERY AND DEVELOPMENT
5.2 RESTRAINTS
5.2.1 DEPENDENCY ON THE MEDICAL AND GENOMIC EXPERT FOR RESULT INTERPRETATION
5.2.2 ETHICAL AND PRIVACY CONCERNS ASSOCIATED WITH PHARMACOGENETIC TESTING
5.3 OPPORTUNITIES
5.3.1 INTEGRATION WITH ELECTRONIC HEALTH RECORDS (EHRS)
5.3.2 ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING INTEGRATION IN HEALTHCARE
5.4 CHALLENGES
5.4.1 CHALLENGES IN CLINICAL IMPLEMENTATION OF PHARMACOGENETICS
5.4.2 COMPLEXITY ASSOCIATED WITH PHARMACOGENETIC TESTING RESULTS
6 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE
6.1 OVERVIEW
6.2 WHOLE GENOME SEQUENCING
6.2.1 NEXT GENERATION SEQUENCING (NGS)
6.2.2 SANGER SEQUENCING
6.3 WHOLE EXOME SEQUENCING
6.3.1 NEXT GENERATION SEQUENCING (NGS)
6.3.2 SANGER SEQUENCING
6.4 ARRAY-BASED TESTS
6.4.1 GLASS SLIDE ARRAYS
6.4.2 IN—SITU SYNTHESIZED ARRAYS
6.4.3 SELF ASSEMBLED ARRAYS
6.5 SINGLE GENE TESTS
6.5.1 NEXT GENERATION SEQUENCING (NGS)
6.5.2 SANGER SEQUENCING
7 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE
7.1 OVERVIEW
7.2 CYP2C19
7.3 CYP2D6
7.4 CYP2C9 AND VKORC1
7.5 CYP1A2
7.6 HLA-B*1502
7.7 HLA-B*5701
7.8 CYP2D
7.9 OPRM1
7.1 ONCOTYPE DX* AND MAMMAPRINT
7.11 DRD3
7.12 D4D4
7.13 SLC6A4
7.14 HTR2A/C
7.15 TMPT
7.16 OTHERS
8 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE
8.1 OVERVIEW
8.2 PRESCRIPTION DRUGS
8.3 NUTRACEUTICALS
8.4 RECREATIONAL DRUGS
8.5 HERBAL SUPPLEMENTS
8.6 VITAMINS
8.7 OVER-THE-COUNTER MEDICATIONS
9 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE
9.1 OVERVIEW
9.2 BLOOD
9.3 SALIVA
10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA
10.1 OVERVIEW
10.2 CARDIOLOGY
10.3 GASTROENTEROLOGY
10.4 ANESTHESIOLOGY
10.5 GENOMICS
10.6 ENDOCRINOLOGY
10.7 IMMUNOLOGY & HYPERSENSITIVITY
10.8 DERMATOLOGY
10.9 GYNECOLOGY
10.1 ONCOLOGY
10.11 NEUROLOGY
10.12 OTHERS
11 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 CLINICAL PRACTICE
11.2.1 SIDE EFFECTS
11.2.2 DRUG EFFECTIVENESS
11.2.3 DOSAGE
11.3 DRUG DEVELOPMENT
11.3.1 DRUG EFFECTIVENESS
11.3.2 DOSAGE
11.3.3 SIDE EFFECTS
11.4 DRUG REGULATION
11.4.1 SIDE EFFECTS
11.4.2 DRUG EFFECTIVENESS
11.4.3 DOSAGE
12 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE PROVIDERS
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.4 RESEARCH CENTRES AND ACADEMIC INSTITUTES
12.5 OTHERS
13 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITAL PHARMACY
13.3 RETAIL PHARMACIES
13.4 MAIL-ORDER PHARMACIES
13.5 DIRECT-TO-CUSTOMER SERVICES
14 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.3 EUROPE
14.4 ASIA-PACIFIC
14.5 SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
15 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 QIAGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SONIC HEALTHCARE
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BGI
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 23ANDME, INC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 DYNAMIC DNA LABORATORIES
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 EUROFINS SCIENTIFIC (2022)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 GENEWIX (A SUBSIDIARY OF AZENTA LIFE SCIENCE)
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 LUMINEX CORPORATION (A SUBSIDIARY OF DIASORIN)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 MD LABS
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 MYRIAD GENETICS, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 ONEOME
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 PACBIO
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PERKINELMER INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 PGXT
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL CYP1A2 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL HLA-B*1502 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL HLA-B*5701 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL CYP2D IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL OPRM1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL ONCOTYPE DX* AND MAMMAPRINT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL DRD3 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL D4D4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL TMPT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL NUTRACEUTICALS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL HERBAL SUPPLEMENTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL VITAMINS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL BLOOD IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL SALIVA IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERPAEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL CARDIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL GASTROENTEROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL ANESTHESIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL GENOMICS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL ENDOCRINOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 GLOBAL IMMUNOLOGY & HYPERSENSITIVITY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL DERMATOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 GLOBAL GYNECOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL ONCOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL NEUROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 53 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 55 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 61 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 U.S. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 U.S. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 U.S. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 86 U.S. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 87 U.S. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 U.S. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 90 U.S. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 91 U.S. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 U.S. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 93 U.S. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 94 U.S. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 95 U.S. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 U.S. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CANADA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 CANADA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 103 CANADA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 105 CANADA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 106 CANADA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 CANADA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 CANADA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 CANADA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 CANADA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 CANADA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 MEXICO PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 113 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 114 MEXICO WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 115 MEXICO ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 121 MEXICO PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 MEXICO CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 123 MEXICO DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 MEXICO DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 MEXICO PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 MEXICO PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 EUROPE PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 128 EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 129 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 EUROPE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 EUROPE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 EUROPE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 134 EUROPE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 EUROPE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 136 EUROPE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 137 EUROPE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 EUROPE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 EUROPE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 EUROPE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 143 GERMANY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 GERMANY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 146 GERMANY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 147 GERMANY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 GERMANY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 149 GERMANY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 GERMANY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 151 GERMANY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 152 GERMANY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 GERMANY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 154 GERMANY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 155 GERMANY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 GERMANY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 157 GERMANY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 158 FRANCE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 159 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 160 FRANCE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 162 FRANCE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 163 FRANCE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 164 FRANCE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 165 FRANCE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 166 FRANCE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 167 FRANCE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 168 FRANCE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 FRANCE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 170 FRANCE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 FRANCE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 172 FRANCE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 173 U.K. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 U.K. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 U.K. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 U.K. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 178 U.K. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 181 U.K. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 182 U.K. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 183 U.K. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 184 U.K. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 185 U.K. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 U.K. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 187 U.K. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 188 ITALY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 194 ITALY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 196 ITALY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 197 ITALY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 198 ITALY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 199 ITALY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 200 ITALY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 201 ITALY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 ITALY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 SPAIN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 SPAIN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 206 SPAIN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 SPAIN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 SPAIN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 209 SPAIN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 SPAIN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 211 SPAIN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 212 SPAIN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 SPAIN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 SPAIN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 SPAIN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 SPAIN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 SPAIN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 221 RUSSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 222 RUSSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 224 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 RUSSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 228 RUSSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 229 RUSSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 RUSSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 232 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 233 TURKEY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 234 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 235 TURKEY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 236 TURKEY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 237 TURKEY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 238 TURKEY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 239 TURKEY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 TURKEY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 241 TURKEY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 242 TURKEY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 243 TURKEY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 244 TURKEY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 245 TURKEY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 246 TURKEY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 247 TURKEY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 264 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 265 NETHERLANDS WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 266 NETHERLANDS ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 267 NETHERLANDS SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 278 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 279 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 SWITZERLAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 281 SWITZERLAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 282 SWITZERLAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 284 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 286 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 287 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 SWITZERLAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SWITZERLAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 SWITZERLAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 291 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 295 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 297 ASIA-PACIFIC WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 299 ASIA-PACIFIC SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 300 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 301 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 302 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 303 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 304 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 305 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 306 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 307 ASIA-PACIFIC DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 308 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 JAPAN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 311 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 312 JAPAN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 313 JAPAN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 314 JAPAN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 315 JAPAN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 316 JAPAN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 JAPAN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 318 JAPAN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 319 JAPAN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 320 JAPAN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 321 JAPAN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 322 JAPAN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 JAPAN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 324 JAPAN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 325 CHINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 328 CHINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 329 CHINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 CHINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 331 CHINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 CHINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 333 CHINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 334 CHINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 335 CHINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 CHINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 CHINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 CHINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 339 CHINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 340 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 341 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 342 SOUTH KOREA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 SOUTH KOREA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 SOUTH KOREA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 346 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 347 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 348 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 349 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 SOUTH KOREA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 SOUTH KOREA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 352 SOUTH KOREA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 354 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 355 INDIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 356 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 357 INDIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 INDIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 359 INDIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 360 INDIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 361 INDIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 INDIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 363 INDIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 364 INDIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 INDIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 366 INDIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 367 INDIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 INDIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 369 INDIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 370 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 371 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 372 AUSTRALIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 AUSTRALIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 374 AUSTRALIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 375 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 376 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 378 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 379 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 380 AUSTRALIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 381 AUSTRALIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 AUSTRALIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 383 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 384 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 385 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 386 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 387 SINGAPORE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 388 SINGAPORE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 389 SINGAPORE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 390 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 391 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 392 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 393 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 394 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 395 SINGAPORE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 396 SINGAPORE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 397 SINGAPORE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 398 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 399 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 400 THAILAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 THAILAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 403 THAILAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 THAILAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 THAILAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 406 THAILAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 407 THAILAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 408 THAILAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 409 THAILAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 410 THAILAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 THAILAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 THAILAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 THAILAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 414 THAILAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 415 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 416 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 417 MALAYSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 418 MALAYSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 419 MALAYSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 420 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 421 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 422 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 423 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 424 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 425 MALAYSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 426 MALAYSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 427 MALAYSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 428 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 429 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 430 INDONESIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 431 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 432 INDONESIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 433 INDONESIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 434 INDONESIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 435 INDONESIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 436 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 437 INDONESIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 438 INDONESIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 439 INDONESIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 440 INDONESIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 441 INDONESIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 442 INDONESIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 443 INDONESIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 444 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 445 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 446 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 447 PHILIPPINES WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 448 PHILIPPINES ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 449 PHILIPPINES SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 450 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 451 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 452 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 453 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 454 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 455 PHILIPPINES CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 456 PHILIPPINES DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 457 PHILIPPINES DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 458 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 459 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 460 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 461 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 462 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 463 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 SOUTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 465 SOUTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 466 SOUTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 467 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 468 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 469 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 470 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 471 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 472 SOUTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 473 SOUTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 474 SOUTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 476 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 477 BRAZIL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 478 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 479 BRAZIL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 480 BRAZIL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 481 BRAZIL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 482 BRAZIL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 483 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 484 BRAZIL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 485 BRAZIL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 486 BRAZIL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 487 BRAZIL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 488 BRAZIL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 489 BRAZIL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 490 BRAZIL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 491 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 492 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 493 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 494 ARGENTINA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 495 ARGENTINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 496 ARGENTINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 497 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 498 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 499 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 500 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 501 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 502 ARGENTINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 503 ARGENTINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 504 ARGENTINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 505 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 506 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 507 REST OF SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 508 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 509 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 510 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 511 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 512 MIDDLE EAST AND AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 513 MIDDLE EAST AND AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 514 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 515 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 516 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 517 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 518 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 519 MIDDLE EAST AND AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 520 MIDDLE EAST AND AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 521 MIDDLE EAST AND AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 522 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 523 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 524 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 525 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 526 SOUTH AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 527 SOUTH AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 528 SOUTH AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 529 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 530 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 532 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 533 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 534 SOUTH AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 535 SOUTH AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 536 SOUTH AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 537 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 538 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 539 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 540 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 541 SAUDI ARABIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 542 SAUDI ARABIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 543 SAUDI ARABIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 544 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 545 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 546 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 547 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 548 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 549 SAUDI ARABIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 550 SAUDI ARABIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 551 SAUDI ARABIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 552 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 553 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 554 U.A.E. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 555 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 556 U.A.E. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 557 U.A.E. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 558 U.A.E. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 559 U.A.E. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 560 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 561 U.A.E. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 562 U.A.E. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 563 U.A.E. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 564 U.A.E. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 565 U.A.E. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 566 U.A.E. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 567 U.A.E. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 568 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 569 ISRAEL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 570 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 571 ISRAEL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 572 ISRAEL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 573 ISRAEL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 574 ISRAEL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 575 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 576 ISRAEL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 577 ISRAEL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 578 ISRAEL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 579 ISRAEL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 580 ISRAEL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 581 ISRAEL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 582 ISRAEL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 583 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 584 EGYPT PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 585 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 586 EGYPT WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 587 EGYPT ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 588 EGYPT SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 589 EGYPT PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 590 EGYPT PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 591 EGYPT PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 592 EGYPT PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 593 EGYPT PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 594 EGYPT CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 595 EGYPT DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 596 EGYPT DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 597 EGYPT PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 598 EGYPT PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 599 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 GLOBAL PHARMACOGENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PHARMACOGENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PHARMACOGENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PHARMACOGENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PHARMACOGENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL PHARMACOGENETIC TESTING MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 10 INCREASING ADOPTION OF PERSONALIZED MEDICINE IS DRIVING THE GROWTH OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING MARKET
FIGURE 13 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2022
FIGURE 14 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2022
FIGURE 18 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2023-2030 (USD MILLION)
FIGURE 19 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, CAGR (2023-2030)
FIGURE 20 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2022
FIGURE 22 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 23 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 24 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2022
FIGURE 26 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2023-2030 (USD MILLION)
FIGURE 27 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, CAGR (2023-2030)
FIGURE 28 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, LIFELINE CURVE
FIGURE 29 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2022
FIGURE 30 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
FIGURE 31 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, CAGR (2023-2030)
FIGURE 32 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, LIFELINE CURVE
FIGURE 33 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2022
FIGURE 34 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2022
FIGURE 38 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 39 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 40 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 42 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 43 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 44 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 GLOBAL PHARMACOGENETIC TESTING MARKET: SNAPSHOT (2022)
FIGURE 46 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 47 NORTH AMERICA PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 48 EUROPE PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 49 AISA-PACIFIC PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
